Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimus neoadjuvant umbrella study in cisplatin-ineligible muscle-invasive bladder cancer
2020-002244-23Phase 2Completed
- Sponsor
- Incyte
- Start
- Mar 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of epacadostat and retifanlimab in transitional cell carcinoma of the bladder (TCC) and muscle-invasive bladder cancer (MIBC), sponsored by Incyte. Primary endpoint: Change from baseline in CD8+ lymphocytes within resected tumor. Started Mar 2021; status: completed.
02
Drugs
epacadostatretifanlimab
03
Conditions
transitional cell carcinoma of the bladder (TCC)muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on 2020-002244-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002244-23.